Axa
KPTI icon

Axa’s Karyopharm Therapeutics KPTI Stock Holding History

Axa’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,467
Closed -$321K – 1309
2020
Q3 		$321K Sell
1,467
-2,086
-59% -$510K ﹤0.01% 1100
2020
Q2 		$1.01M Hold
3,553
– – ﹤0.01% 945
2020
Q1 		$1.02M Buy
+3,553
New +$980K 0.01% 848

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Axa's KPTI Position: Q4 2020 in Review

Axa sold out of Karyopharm Therapeutics (KPTI) in Q4 2020, closing a stake of 1,467 shares — an estimated $321K sold.

Axa first reported a position in KPTI in Q1 2020 and held it in 3 quarters. The position peaked at $1.02M in Q1 2020. 168 funds tracked by Wall St. Rank hold KPTI as of Q4 2020.

  • Axa reported no remaining Karyopharm Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Axa sold 1,467 Karyopharm Therapeutics shares in Q4 2020, an estimated $321K.
  • Axa first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 3 quarters.
  • Axa's Karyopharm Therapeutics position peaked at $1.02M in Q1 2020.
  • 168 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2020.

Based on Axa's 13F filing for Q4 2020, filed 12 Feb 2021.